Abstract
The CD19 molecule is ubiquitously expressed throughout all stages of B-cell differentiation, but is not found on haemopoietic stem cells. Since most B-cell leukaemias and lymphomas retain CD19 expression, it represents an excellent target for immunotherapy of these malignant disorders. Over the past 10 years, compelling pre-clinical evidence has accrued to indicate that expression of a CD19-targeted chimeric antigen receptor (CAR) in peripheral blood T-cells exerts therapeutic efficacy in diverse models of B-cell malignancy. Building on this, clinical studies are ongoing in several centres in which autologous CD19-specific CAR T-cells are undergoing evaluation in patients with acute and chronic B-cell leukaemia and refractory lymphoma. Early data have generated considerable excitement, providing grounds to speculate that CAR-based immunotherapy will radically alter existing management paradigms in B-cell malignancy. The focus of this mini-review is to evaluate these emerging clinical data and to speculate on clinical prospects for this new therapeutic modality.
Keywords: Adoptive immunotherapy, CD19, chimeric antigen receptor, gene therapy, leukaemia, lymphoma.
Current Gene Therapy
Title:Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Volume: 14 Issue: 1
Author(s): John Maher
Affiliation:
Keywords: Adoptive immunotherapy, CD19, chimeric antigen receptor, gene therapy, leukaemia, lymphoma.
Abstract: The CD19 molecule is ubiquitously expressed throughout all stages of B-cell differentiation, but is not found on haemopoietic stem cells. Since most B-cell leukaemias and lymphomas retain CD19 expression, it represents an excellent target for immunotherapy of these malignant disorders. Over the past 10 years, compelling pre-clinical evidence has accrued to indicate that expression of a CD19-targeted chimeric antigen receptor (CAR) in peripheral blood T-cells exerts therapeutic efficacy in diverse models of B-cell malignancy. Building on this, clinical studies are ongoing in several centres in which autologous CD19-specific CAR T-cells are undergoing evaluation in patients with acute and chronic B-cell leukaemia and refractory lymphoma. Early data have generated considerable excitement, providing grounds to speculate that CAR-based immunotherapy will radically alter existing management paradigms in B-cell malignancy. The focus of this mini-review is to evaluate these emerging clinical data and to speculate on clinical prospects for this new therapeutic modality.
Export Options
About this article
Cite this article as:
Maher John, Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells, Current Gene Therapy 2014; 14 (1) . https://dx.doi.org/10.2174/1566523213666131223130554
DOI https://dx.doi.org/10.2174/1566523213666131223130554 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Anticancer Drugs in Reproductive Parameters of Juvenile Male Animals and Role of Protective Agents
Anti-Cancer Agents in Medicinal Chemistry Clinical Proteomics in Cancer Research
Current Proteomics Design, Synthesis and Antiproliferative Activity of 2-Acetamidothiazole-5- carboxamide Derivatives
Medicinal Chemistry HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study
Current Drug Targets Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Thioredoxin System Modulation by Plant and Fungal Secondary Metabolites
Current Medicinal Chemistry Parallel Gene Expression Profiling of Mantle Cell Lymphoma – How Do We Transform ´Omics Data into Clinical Practice
Current Genomics Fanconi Anemia Proteins, DNA Interstrand Crosslink Repair Pathways, and Cancer Therapy
Current Cancer Drug Targets Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Anti-Cancer Agents in Medicinal Chemistry Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Daphnane-Type Diterpene Orthoesters and their Biological Activities
Mini-Reviews in Medicinal Chemistry miRNAs in Bone Development
Current Genomics Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA
Protein & Peptide Letters Advances and Application of DNA-functionalized Nanoparticles
Current Medicinal Chemistry Synthesis of Nitroaromatic Compounds as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets